Works matching IS 19466234 AND DT 2024 AND VI 16 AND IP 751

Results: 5
    1
    2

    Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation.

    Published in:
    Science Translational Medicine, 2024, v. 16, n. 751, p. 1, doi. 10.1126/scitranslmed.adj9672
    By:
    • Vinnakota, Janaki Manoja;
    • Adams, Rachael C.;
    • Athanassopoulos, Dimitrios;
    • Schmidt, Dominik;
    • Biavasco, Francesca;
    • Zähringer, Alexander;
    • Erny, Daniel;
    • Schwabenland, Marius;
    • Langenbach, Marlene;
    • Wenger, Valentin;
    • Salié, Henrike;
    • Cook, James;
    • Mossad, Omar;
    • Andrieux, Geoffroy;
    • Dersch, Rick;
    • Rauer, Sebastian;
    • Duquesne, Sandra;
    • Monaco, Gianni;
    • Wolf, Phillipp;
    • Blank, Thomas
    Publication type:
    Article
    3

    Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.

    Published in:
    Science Translational Medicine, 2024, v. 16, n. 751, p. 1, doi. 10.1126/scitranslmed.adi5336
    By:
    • Khalaf, Ahmed;
    • de Beauchamp, Lucie;
    • Kalkman, Eric;
    • Rattigan, Kevin;
    • Himonas, Ekaterini;
    • Jones, Joe;
    • James, Daniel;
    • Shokry, Engy Shokry Abd;
    • Scott, Mary T.;
    • Dunn, Karen;
    • Tardito, Saverio;
    • Copland, Mhairi;
    • Sumpton, David;
    • Shanks, Emma;
    • Helgason, G. Vignir
    Publication type:
    Article
    4
    5